Defining the Ablative Dose for Y-90 TARE
ConditionHCC - Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthwestern University
About this trial
This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.
Eligibility criteria
Qualifiers
Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.
Age ≥18 years.
Tumor size ≤5 cm requiring treatment of ≤2 Couinaud segments.
Child-Pugh class A or B liver function
Disqualifiers
Extrahepatic metastases.
Pregnant or breastfeeding individuals.
Tumors requiring treatment of more than two Couinaud segments.
Known hypersensitivity to gadolinium-based contrast agents.
Trial design
Treatments tested in this trial
- Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Northwestern University
Lead sponsor
Radiological Society of North America
Collaborator
Robert H. Lurie Cancer Center
Collaborator
Source ClinicalTrials.gov